SINT · Sintx Technologies, Inc.
$1.51
-0.05 (-3.21%)
At close · Jul 29
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Despite the actions undertaken by management to improve liquidity and operating costs—including the divestiture of non-core operations, implementation of cost improvement initiatives, commercialization of newly cleared medical products, access to capital through the Company’s ATM program, and execution of the Armor facility sublease—management has concluded that substantial doubt remains regarding the Company’s ability to continue as a going concern for a period of at least 12 months from the date these condensed consolidated financial statements are issued.”View the 10-Q filed May 15, 2026
Market Cap
$6.52M
Shares
4.32M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| B. Sonny Bal | CEO | $440,651 |
| David O’Brien | COO | $369,824 |
| Eric Olson | CEO | $194,594 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| B. Sonny Bal | CEO | $537,312 |
| David O’Brien | COO | $453,602 |
| Eric Olson | CEO | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| B. Sonny Bal | CEO | $511,784 |
| David O’Brien | COO | $391,903 |
| Bryan J. McEntire | Chief Scientific Officer | $9,283 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| B. Sonny Bal | CEO | $483,087 |
| David O’Brien | COO | $370,219 |
| Bryan J. McEntire | Chief Scientific Officer | $312,060 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| B. Sonny Bal | CEO | $487,442 |
| David O’Brien | COO | $346,207 |
| Bryan J. McEntire | Chief Scientific Officer | $297,673 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| B. Sonny Bal | CEO | $401,231 |
| Bryan J. McEntire | Chief Scientific Officer | $249,313 |
| David O’Brien | COO | $242,152 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| B. Sonny Bal | CEO | $411,693 |
| Bryan J. McEntire | Chief Scientific Officer | $244,357 |
| David O’Brien | COO | $226,588 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Ryan Elmore | President | Appointed | 2026-02-18 |
| Kevin Trask | Chief Financial Officer | Appointed | 2025-09-05 |